Brunner F P, Wenk M, Mauracher E, Thiel G, Follath F
Schweiz Med Wochenschr. 1982 Jun 26;112(26):934-41.
Aminoglycoside antibiotics are useful--despite potential toxicity--for treating urinary tract infection when other antibacterial agents have failed to eradicate bacteriuria. That this is true of the recently introduced aminoglycoside netilmicin was shown by 16 cases of tenacious and frequently recurring urinary tract infection. In contrast to previous recommendations, but relying on well known pharmacokinetic data which show prolonged urinary excretion of aminoglycosides, netilmicin was administered according to the following dosage schedule: Intramuscular injections of 3 mg/kg in cases where renal function was unimpaired, and of 2 mg/kg where it was reduced, were administered at dosage intervals of 1 to 4 days. Peak serum levels of netilmicin measured 1 hour after intramuscular injection were within the expected range of 8-14 micrograms/ml (3 mg/kg) and 6-10 micrograms/ml (2 mg/kg). As a result of the long dosage intervals the serum trough levels were usually far below 1 microgram/ml except in patients with moderate renal failure. Urinary concentrations of netilmicin, however, remained for the most part above the limit of antibacterial activity throughout the dosage intervals of 1 to 4 days. One week after the usual three weeks treatment course, urinary concentrations were still between 1 and 5 mcg/ml, and slowly decreasing amounts of the drug could be detected at least in traces up to 3 months beyond the last dose. Considering the type of urinary tract infections selected to receive netilmicin, the response to treatment was satisfactory and seemed unaffected by the long dosage intervals. Bacteriological cure was achieved in 5 of 11 infections associated with chronic pyelonephritis or analgesic nephropathy and in 4 of 5 urinary infections in patients with renal transplants. Treatment failures could be accounted for by obstructive lesions, stones, and in one transplanted patient by infection localized to her own shrunken kidneys. No instance of ototoxicity or nephrotoxicity due to netilmicin could be detected. Netilmicin administered according to the dosage schedule described can be recommended for ambulatory treatment of tenacious, recurring urinary tract infections due to gram-negative bacteria and refractory to cure by the usual oral antibiotic therapy.
氨基糖苷类抗生素尽管存在潜在毒性,但在其他抗菌药物未能根除菌尿时,对于治疗尿路感染是有用的。16例顽固且频繁复发的尿路感染病例表明,最近引入的氨基糖苷类药物奈替米星确实如此。与先前的建议相反,但依据显示氨基糖苷类药物尿排泄延长的知名药代动力学数据,奈替米星按以下剂量方案给药:肾功能未受损时,肌内注射3mg/kg;肾功能降低时,肌内注射2mg/kg,给药间隔为1至4天。肌内注射后1小时测得的奈替米星血清峰值水平在预期范围内,即8 - 14微克/毫升(3mg/kg)和6 - 10微克/毫升(2mg/kg)。由于给药间隔时间长,除中度肾衰竭患者外,血清谷值水平通常远低于1微克/毫升。然而,在1至4天的给药间隔期间,奈替米星的尿浓度大部分时间仍高于抗菌活性限度。在通常为期三周的治疗疗程结束一周后,尿浓度仍在1至5微克/毫升之间,并且至少在末次给药后3个月内仍能检测到少量逐渐减少的药物。考虑到选择接受奈替米星治疗的尿路感染类型,治疗反应令人满意,且似乎不受长给药间隔的影响。在11例与慢性肾盂肾炎或镇痛剂肾病相关的感染中,5例实现了细菌学治愈;在5例肾移植患者的尿路感染中,4例实现了细菌学治愈。治疗失败可能是由于梗阻性病变、结石,以及1例移植患者自身萎缩肾脏局部感染所致。未检测到因奈替米星引起的耳毒性或肾毒性实例。按照所述剂量方案给药的奈替米星可推荐用于门诊治疗由革兰氏阴性菌引起的、顽固且复发的尿路感染,以及常规口服抗生素治疗难以治愈的尿路感染。